Beijing Tide Pharmaceutical Co., Ltd.

Bioardis LLC

Ning Shao

Jing Li

Hongjun Wang

Liying Zhou

Yanping Zhao

Yuanyuan Jiang

Yeming Wang

Fengping Xiao

Yanan Liu

Gong Li

Huai Huang

Zhenguang Zou

Kai Liu

Frank Kayser

Ding Wang

Fajie Li

Hongbin Yuan

Xiang Li

The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof.

Receptor inhibitor, pharmaceutical composition comprising same, and use thereof

The present disclosure relates generally to aromatic derivatives that are inhibitors of FGFR4 and are useful in treating FGFR4-associated diseases or conditions. Compositions containing the compounds of the present disclosure are also provided.

Aromatic derivatives, preparation methods, and medical uses thereof

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist.

P2X3 andor P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

The present invention discloses a receptor inhibitor of formula (I), a composition comprising the same and the usage thereof.

Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof

The present invention discloses a receptor inhibitor of formula (I), a pharmaceutical composition comprising the same and the use thereof. 

A P2X3 and/or P2X2/3 receptor antagonist of formula (I), a pharmaceutical composition comprising the same, and a use thereof in preparing a drag for preventing or treating a disease mediated by the P2X3 and/or P2X2/3 receptor antagonist. 

P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof

An aromatic derivative as represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising same, a preparation method therefor, and uses of the aromatic derivative and the pharmaceutically acceptable salt thereof or the pharmaceutical composition comprising same in preparing a therapeutic agent, specifically an FGFR4 tyrosine kinase inhibitor, and in preparing a medicament for treating and/or preventing neoplastic and inflammatory diseases. The substituents of formula (I) are same as defined in the description. 

Growing community of inventors

Beijing, China

Ning Shao